Grace Therapeutics, Inc. (GRCE) Current Ratio
- Current ratio · latest quarter: Value 11.47×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 11.47× | Current assets / current liabilities. $14.33M ÷ $1.25M ≈ 11.47× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 14.33M USD | Assets, Current |
| Current obligations | 1.25M USD | Liabilities, Current |
| Cash and equivalents | 13.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.33M | $1.25M | $13.76M | (m) | (m) | (m) | (m) | (m) | 11.47× |
| 2026-03-31 | $17.38M | $2.15M | $16.98M | (m) | (m) | (m) | (m) | (m) | 8.10× |
| 2025-12-31 | $19.21M | $1.28M | $18.67M | (m) | (m) | (m) | (m) | (m) | 14.96× |
| 2025-09-30 | $17.30M | $1.25M | $16.86M | (m) | (m) | (m) | (m) | (m) | 13.89× |
| 2025-06-30 | $20.52M | $2.31M | $20.00M | (m) | (m) | (m) | (m) | (m) | 8.87× |
| 2025-03-31 | $22.71M | $1.93M | $22.13M | (m) | (m) | (m) | (m) | (m) | 11.77× |
| 2024-12-31 | $11.94M | $1.97M | $11.05M | (m) | (m) | (m) | (m) | (m) | 6.06× |
| 2024-09-30 | $16.06M | $2.67M | $15.15M | (m) | (m) | (m) | (m) | (m) | 6.01× |
| 2024-06-30 | $20.43M | $2.60M | $19.39M | (m) | $398.00K | (m) | (m) | (m) | 7.86× |
| 2024-03-31 | $24.01M | $1.68M | $23.00M | (m) | (m) | (m) | (m) | (m) | 14.26× |
| 2023-12-31 | $26.88M | $1.77M | $18.55M | (m) | $959.00K | (m) | (m) | (m) | 15.19× |
| 2023-09-30 | $28.89M | $1.40M | $26.99M | (m) | $837.00K | (m) | (m) | (m) | 20.68× |
| 2023-06-30 | $23.61M | $1.97M | $21.63M | (m) | $837.00K | (m) | (m) | (m) | 12.01× |
| 2023-03-31 | $29.29M | $3.41M | $27.88M | (m) | $802.00K | (m) | (m) | (m) | 8.59× |
| 2022-12-31 | $33.43M | $3.43M | $26.24M | (m) | (m) | (m) | (m) | (m) | 9.74× |
| 2022-09-30 | $37.51M | $3.81M | $34.93M | (m) | (m) | (m) | (m) | (m) | 9.86× |
| 2022-06-30 | $41.25M | $3.71M | $38.38M | (m) | (m) | (m) | (m) | (m) | 11.13× |
| 2022-03-31 | $45.28M | $3.26M | $30.34M | (m) | $548.00K | (m) | (m) | (m) | 13.89× |
| 2021-12-31 | $49.00M | $2.90M | $33.01M | (m) | (m) | (m) | (m) | (m) | 16.91× |
| 2021-09-30 | $54.55M | $4.48M | $36.93M | (m) | (m) | (m) | (m) | (m) | 12.19× |
| 2021-06-30 | $60.39M | $2.35M | $40.98M | (m) | (m) | (m) | (m) | (m) | 25.75× |
| 2021-03-31 | $62.37M | $1.58M | $50.94M | (m) | $530.00K | (m) | (m) | (m) | 39.50× |
| 2020-12-31 | $30.20M | $2.25M | $26.55M | (m) | (m) | $14.00K | (m) | (m) | 13.43× |
| 2020-09-30 | $13.71M | $3.75M | $11.55M | (m) | (m) | (m) | (m) | (m) | 3.66× |
| 2020-06-30 | $13.96M | $5.98M | $12.12M | (m) | (m) | (m) | (m) | (m) | 2.34× |
| 2020-03-31 | $18.46M | $7.39M | $14.24M | (m) | $546.00K | (m) | (m) | (m) | 2.50× |
| 2019-03-31 | $27.97M | $13.67M | $16.87M | $8.89M | $1.19M | (m) | (m) | (m) | 2.05× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |